Drug
Migalastat
Migalastat: highest development phase Phase 3, developed by Amicus Therapeutics. 15 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amicus Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| migalastat hydrochloride NCT01218659 | Phase 3 | Fabry Disease |
| migalastat hydrochloride NCT01458119 | Phase 3 | Fabry Disease |
| migalastat HCl 150 mg NCT02194985 | Phase 3 | Fabry Disease |
| migalastat HCl 150 mg NCT04049760 | Phase 3 | Fabry Disease |
| Migalastat HCl 20 mg NCT06904261 | Phase 3 | Fabry Disease |
| migalastat hydrochloride NCT00925301 | Phase 3 | Fabry Disease |
| migalastat HCl 150 mg NCT04020055 | Phase 3 | Fabry Disease |
| Migalastat HCl 150 mg NCT03500094 | Phase 3 | Fabry Disease |
| migalastat HCl NCT00283933 | Phase 2 | Fabry Disease |
| migalastat HCl NCT00304512 | Phase 2 | Fabry Disease |
| Migalastat HCl NCT01196871 | Phase 2 | Fabry Disease |
| migalastat HCl NCT00526071 | Phase 2 | Fabry Disease |
| migalastat HCl NCT00214500 | Phase 2 | Fabry Disease |
| migalastat HCl NCT00283959 | Phase 2 | Fabry Disease |
| IV migalastat HCl NCT02082327 | Phase 1 | Fabry Disease |
Latest
No recent events.
Follow Migalastat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.